MicroRNA-18a is elevated in prostate cancer and promotes tumorigenesis through suppressing STK4 in vitro and in vivo

Oncogenesis

Volumn 3, Issue 4, 2014, Pages

  Hsu, T I ^a   Hsu, C H ^b   Lee, K H ^c   Lin, J T ^a,d   Chen, C S ^a   Chang, K C ^e   Su, C Y J ^f   Hsiao, M ^f   Lu, P J ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

miR 18a; prostate cancer; STK4

Indexed keywords

MICRORNA; MICRORNA 18A; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SERINE THREONINE PROTEIN KINASE 4; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING SITE; BIOINFORMATICS; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CELL GROWTH; CONTROLLED STUDY; DEPHOSPHORYLATION; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

MUS MUSCULUS;

EID: 84906831624     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.12     Document Type: Article

References (44)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Le Quesne JP, Spriggs KA, Bushell M, Willis AE. Dysregulation of protein synthesis and disease. J Pathol 2010; 220: 140-151.
3. Visone R, Petrocca F, Croce CM. Micro-RNAs in gastrointestinal and liver disease. Gastroenterology 2008; 135: 1866-1869.
4. Murray MY, Rushworth SA, MacEwan DJ. Micro RNAs as a new therapeutic target towards leukaemia signalling. Cell Signal 2012; 24: 363-368.
5. Deng JH, Deng Q, Kuo CH, Delaney SW, Ying SY. MiRNA targets of prostate cancer. Methods Mol Biol 2013; 936: 357-369.
6. Lee KH, Chen YL, Yeh SD, Hsiao M, Lin JT, Goan YG et al. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 2009; 28: 3360-3370.
7. Yu G, Tang JQ, Tian ML, Li H, Wang X, Wu T et al. Prognostic values of the miR-17-cluster and its paralogs in colon cancer. J Surg Oncol 2012; 106: 232-237.
8. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65: 9628-9632.
9. Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, Thiruchelvam P et al. The estrogen receptor-Alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci USA 2009; 106: 15732-15737.
10. Luo Z, Dai Y, Zhang L, Jiang C, Li Z, Yang J et al. miR-18a promotes malignant progression by impairing microRNA biogenesis in nasopharyngeal carcinoma. Carcinogenesis 2013; 34: 415-425.
11. Morimura R, Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Nagata H et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 2011; 105: 1733-1740.
12. Vega AB, Pericay C, Moya I, Ferrer A, Dotor E, Pisa A et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep 2013; 30: 320-326.
13. Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JR et al. Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod Pathol 2007; 20: 331-338.
14. Seidel C, Schagdarsurengin U, Blumke K, Wurl P, Pfeifer GP, Hauptmann S et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 2007; 46: 865-871.
15. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009; 16: 425-438.
16. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA 2010; 107: 1437-1442.
17. Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci USA 2010; 107: 1431-1436.
18. Creasy CL, Ambrose DM, Chernoff J. The Ste20-like protein kinase, Mst1, dimerizes and contains an inhibitory domain. J Biol Chem 1996; 271: 21049-21053.
19. Taylor LK, Wang HC, Erikson RL. Newly identified stress-responsive protein kinases, Krs-1 and Krs-2. Proc Natl Acad Sci USA 1996; 93: 10099-10104.
20. Cinar B, Fang PK, Lutchman M, Di Vizio D, Adam RM, Pavlova N et al. The proapoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. EMBO J 2007; 26: 4523-4534.
21. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
22. Dogar AM, Towbin H, Hall J. Suppression of latent transforming growth factor (TGF)-beta1 restores growth inhibitory TGF-beta signaling through microRNAs. J Biol Chem 2011; 286: 16447-16458.
23. Li L, Shi JY, Zhu GQ, Shi B. MiR-17-92 cluster regulates cell proliferation and collagen synthesis by targeting TGFB pathway in mouse palatal mesenchymal cells. J Cell Biochem 2012; 113: 1235-1244.
24. Fox JL, Dews M, Minn AJ, Thomas-Tikhonenko A. Targeting of TGFbeta signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma. RNA 2013; 19: 177-190.
25. Cheung WL, Ajiro K, Samejima K, Kloc M, Cheung P, Mizzen CA et al. Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. Cell 2003; 113: 507-517.
26. Ura S, Masuyama N, Graves JD, Gotoh Y. Caspase cleavage of MST1 promotes nuclear translocation and chromatin condensation. Proc Natl Acad Sci USA 2001; 98: 10148-10153.
27. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol 2009; 24: 652-657.
28. Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H et al. Over-And under-expressed microRNAs in human colorectal cancer. Int J Oncol 2009; 34: 1069-1075.
29. Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L et al. MicroRNA profiling of human gastric cancer. Mol Med Rep 2009; 2: 963-970.
30. Zhang ZW, An Y, Teng CB. The roles of miR-17-92 cluster in mammal development and tumorigenesis. Yi Chuan 2009; 31: 1094-1100.
31. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 2010; 11: 50-54.
32. Yeh SH, Chen PJ. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology 2010; 78(Suppl 1): 172-179.
33. Alencar AJ, Malumbres R, Kozloski GA, Advani R, Talreja N, Chinichian S et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res 2011; 17: 4125-4135.
34. Brock M, Trenkmann M, Gay RE, Gay S, Speich R, Huber LC. MicroRNA-18a enhances the interleukin-6-mediated production of the acute-phase proteins fibrinogen and haptoglobin in human hepatocytes. J Biol Chem 2011; 286: 40142-40150.
35. Yang Y, Ding L, An Y, Zhang ZW, Lang Y, Tai S et al. MiR-18a regulates expression of the pancreatic transcription factor Ptf1a in pancreatic progenitor and acinar cells. FEBS Lett 2012; 586: 422-427.
36. Wu W, Takanashi M, Borjigin N, Ohno SI, Fujita K, Hoshino S et al. MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis. Br J Cancer 2013; 108: 653-661.
37. Yang X, Du WW, Li H, Liu F, Khorshidi A, Rutnam ZJ et al. Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Res 2013; 41: 9688-9704.
38. Sikand K, Slane SD, Shukla GC. Intrinsic expression of host genes and intronic miRNAs in prostate carcinoma cells. Cancer Cell Int 2009; 9: 21.
39. Xu Y, Fang F, Zhang J, Josson St S, Clair St WH, Clair DK. miR-17 suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymes. PLoS One 2010; 5: e14356.
40. Kim K, Chadalapaka G, Pathi SS, Jin UH, Lee JS, Park YY et al. Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25 clusters. Mol Cancer Ther 2012; 11: 1852-1862.
41. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F et al. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem 2007; 282: 2135-2143.
42. Lee KK, Ohyama T, Yajima N, Tsubuki S, Yonehara S. MST, a physiological caspase substrate, highly sensitizes apoptosis both upstream and downstream of caspase activation. J Biol Chem 2001; 276: 19276-19285.
43. Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999; 274: 34967-34973.
44. Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY et al. MicroRNA-18a prevents estrogen receptor-Alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 2009; 136: 683-693.